Alkermes (ALKS) Research & Development (2010 - 2026)
Alkermes' Research & Development was $112.92 million in Q2 2026, up 45.9% from $77.37 million a year earlier and up 9.3% from the prior quarter.
Powered by 
Analysis
Alkermes (ALKS) Research & Development (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Alkermes' Research & Development was $391.04 million through Jun 30, 2026, up 46.3% year-over-year; for FY2025, it came in at $323.96 million, up 32.1% from FY2024.
- Research & Development shows a five-year compound annual growth rate of -3.9% (FY2020 to FY2025).
- In earlier years, Research & Development was $245.33 million in FY2024 (-9.4%), $270.81 million in FY2023 (-0.7%), $272.7 million in FY2022 (-6.3%) and $290.92 million in FY2021 (-26.3%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q3 2021.
- Compared with a year earlier, Research & Development has increased for six straight quarters, with growth averaging 24.1% over the last eight quarters.
- The best year-over-year quarter for Research & Development over five years was Q4 2025 (growth of 59.9%); the worst was Q3 2023 (a decline of 35.4%).
- Per Business Quant data, ALKS's Research & Development in the three quarters before Q2 2026 was $103.35 million (Q1 2026), $93.04 million (Q4 2025) and $81.74 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Alkermes | 6.73 Bn | 3.86 Bn | 397.90 Mn | 112.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 112.92 Mn |
| Mar 31, 2026 | 103.35 Mn |
| Dec 31, 2025 | 93.04 Mn |
| Sep 30, 2025 | 81.74 Mn |
| Jun 30, 2025 | 77.37 Mn |
| Mar 31, 2025 | 71.82 Mn |
| Dec 31, 2024 | 58.17 Mn |
| Sep 30, 2024 | 59.89 Mn |
| Jun 30, 2024 | 59.65 Mn |
| Mar 31, 2024 | 67.61 Mn |
| Dec 31, 2023 | 73.93 Mn |
| Sep 30, 2023 | 64.88 Mn |
| Jun 30, 2023 | 68.23 Mn |
| Mar 31, 2023 | 63.77 Mn |
| Dec 31, 2022 | -16.55 Mn |
| Sep 30, 2022 | 100.43 Mn |
| Jun 30, 2022 | 92.87 Mn |
| Mar 31, 2022 | 95.95 Mn |
| Dec 31, 2021 | -17.23 Mn |
| Sep 30, 2021 | 118.41 Mn |
API Access
Alkermes Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ALKS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ALKS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ALKS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();